10x Genomics, Inc. · NASDAQ:TXG
10x Genomics — Morgan Stanley Virtual Healthcare Conference 2020
41 slides from 10x Genomics's conference presentation, September 2020
Slide 1: Serge Saxonov, CEO, Co-Founder
Serge Saxonov CEO, Co-Founder September 2020
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe har
Slide 3: 10x Today
10x Today $246M 2019 revenue 68% Yearly revenue growth in 2019 1,650+ Instruments installed as of 2019 $150K+ Consumable pull-through 1,500+ Peer reviewed publications Note: Annual consumable pull-through per instrument as of FY 2019. Peer reviewed publications as of September 3, 2020. © 10X GENOMIC
Slide 4: Significant Progress Since the IPO
Significant Progress Since the IPO © 10X GENOMICS, INC. 2020. 4
Slide 5: Century of Biology
Century of Biology © 10X GENOMICS, INC. 2020. 5
Slide 6: Biology is Immensely Complex
Biology is Immensely Complex 3 billion DNA bases in the genome Each cell with its own epigenetic program Transcribed into tens of thousands of mRNA molecules Each cell with a unique set of expressed genes 40 trillion cells Translated into tens of thousands of proteins Each immune cell with its own u
Slide 7: The Need for High Resolution at Massive Scale
The Need for High Resolution at Massive Scale Genomics-Led Path to Understanding Human Biology Second Phase First Phase Focus on DNA Expand to address all of biology Compile the ‘parts list’ Understand the parts and of human biology learn how to manipulate them Human Genome Project Genome wide assoc
Slide 8: Gene Expression at the Right Resolution and Scale
Gene Expression at the Right Resolution and Scale Conventional gene expression Single cell data for thousands of cells tSNE2 tSNE2 tSNE1 tSNE1 Note: t-SNE projection of approximately 10,000 mouse brain cells derived from the combined cortex, hippocampus and ventricular zones of embryonic day 18 brai
Slide 9: Major Discoveries Across Life Sciences
Major Discoveries Across Life Sciences © 10X GENOMICS, INC. 2020. 9
Slide 10: Deep Expertise Across Diverse Disciplines
Deep Expertise Across Diverse Disciplines Hardware Chemistry Biology Software Data © 10X GENOMICS, INC. 2020. 10
Slide 11: Complete Solutions
Complete Solutions Instruments Consumables Software © 10X GENOMICS, INC. 2020. 11
Slide 12: Innovation Engine
Innovation Engine Chromium Connect Next GEM Platform Cell Surface CRISPR Antigen Targeted Single (v2) High Definition Proteins Profile Specificity Cell Gene Expression Immunology Visium Platform Single Cell High Definition Single Cell Single Cell (v3) Single Cell Single Cell Multiome Gene Expression
Slide 13: Product Platforms
Product Platforms Traditional Platforms Chromium Visium . Bulk Single Cell Spatial © 10X GENOMICS, INC. 2020. 13
Slide 14: Chromium Platform: Millions of Parallel Reactions
Chromium Platform: Millions of Parallel Reactions Sample Chromium Controller Next generation Analysis and and consumables sequencer visualization software Fewer than 25% of customers own a DNA sequencer © 10X GENOMICS, INC. 2020. 14
Slide 15: Visium Platform: Rich Spatial Characterization
Visium Platform: Rich Spatial Characterization Sample Visium Next generation Analysis and consumables sequencer visualization software Fewer than 25% of customers own a DNA sequencer © 10X GENOMICS, INC. 2020. 15
Slide 16: Acquisition of Cartana
Acquisition of Cartana • Technology and IP for In Situ interrogation of tissues • Complementary to our Chromium and Visium platforms • Founded by a group of scientists from Stockholm University and Karolinska Institute, including In Situ analysis pioneer Mats Nilsson • Total consideration of $41.2 m
Slide 17: Rapid Growth in Publications Across Life Science
Rapid Growth in Publications Across Life Science Cumulative publications 2016 2017 2018 2019 2020 Note: Publications published based on data generated using our products. Represents cumulative publications per quarter. © 10X GENOMICS, INC. 2020. 17
Slide 18: Replacing the Legacy Toolkit Across Biology
Replacing the Legacy Toolkit Across Biology © 10X GENOMICS, INC. 2020. 18
Slide 19: Underpenetrated Market: Real-Time PCR Comparison
Underpenetrated Market: Real-Time PCR Comparison ~50,000 1,993 Real-Time PCR Units Globally Chromium Instruments Large market opportunity Note: 10x estimates for RT-PCR data are based on market research. Chromium instruments sold are as of June 30, 2020. © 10X GENOMICS, INC. 2020. 19
Slide 20: Creating New Markets Across Life Science Research
Creating New Markets Across Life Science Research Science and tools-based transformation of healthcare Global life science research tools $50B+ Applications where 10x offers immediate alternatives or is complementary $13B We view much of this Adoption within total market high throughput opportunity
Slide 21: Focused and Experienced Commercial Organization
Focused and Experienced Commercial Organization 97 of the top 100 global research institutions today 19 of top 20 global biopharmaceutical companies today Industry Leadership Named partner Human Cell Atlas and other large projects 1,993 instruments sold as of June 30, 2020 Low customer concentration
Slide 22: Chromium Use Case: University of Pittsburgh
Chromium Use Case: University of Pittsburgh Single cell genomics core facility supports early adoption One placement has grown to 14 Individual placements are typically shared by several labs with between 2-5 users University of Pittsburgh outsources nearly all of its sequencing to third- party prov
Slide 23: Global Commercial Footprint
Global Commercial Footprint North America EMEA APAC 52% of revenue 22% of revenue 26% of revenue High touch direct organization of 250+ FTEs with 100+ commissioned sales executives Direct in North America and most EU countries with commercial partners supporting the rest of world Note: Revenue by ge
Slide 24: 775+ Patents Issued / Filed
775+ Patents Issued / Filed Chromium Single Cell Visium Spatial Key Platforms Technologies Partitioning techniques Array designs and fabrication Barcoding assays Spatial barcoding Instrumentation and software Sample preparation Key Application Areas Gene Expression Immunology DNA Epigenomics Protein
Slide 25: Exceptional Financial Profile
Exceptional Financial Profile Revenue ($mm) +49% y/y +34% y/y +76% +67% y/y 68% +96% 2019 Revenue growth y/y +97% y/y y/y (23%) +97% y/y y/y +113% +128% y/y y/y 2017 2018 2019 2020 $158k 78% ~83% Instrument pull-through Gross margin Revenue from consumables Note: Annual consumable pull-through per i
Slide 26: Appendix
Appendix © 10X GENOMICS, INC. 2020. 26
Slide 27: Targeted Gene Expression
Targeted Gene Expression ● More flexibility ● More scale ● More applications Single Cell Single Cell Spatial Gene Expression Immune Profiling Gene Expression Note: Targeted single cell gene expression and immune profiling launched in May 2020. Targeted spatial gene expression expected launch date in
Slide 28: Targeted Gene Expression, Built the 10x Way
Targeted Gene Expression, Built the 10x Way Hybrid capture enrichment for versatile, sensitive, customizable targeting Note: Targeted single cell gene expression and immune profiling launched in May 2020. Targeted spatial gene expression expected launch date in Fall 2020. © 10X GENOMICS, INC. 2020.
Slide 29: Ready-to-use 10x Genomics Content Offering
Ready-to-use 10x Genomics Content Offering Fixed gene panels with comprehensive content • Tissue specific marker genes • Major signaling pathways Human Pan-Cancer Human Gene Signature • Common biomarkers ~1250 genes ~1140 genes • Disease targets for drug discovery Human Immunology Human Neuroscience
Slide 30: From Discovery to Focused Transcriptomics
From Discovery to Focused Transcriptomics Targeted product built for 10x assays Increased experimental efficiency Reduced sequencing cost WTA and targeted gene expression from the same cells Expected 80% 80%reduction reduction Core assay compatibility Content and customization © 10X GENOMICS, INC. 2
Slide 31: Chromium Single-cell Multiome ATAC+Gene Expression
Chromium Single-cell Multiome ATAC+Gene Expression • Deeply characterize cell types and states • Connect regulatory elements and gene activity • Interpret epigenetic profiles using expression markers Note: Chromium Single-cell Multiome ATAC+Gene Expression announced and made available for pre-order
Slide 32: Unlocking Rules of Epigenetic Programming
Unlocking Rules of Epigenetic Programming DNA Epigenome RNA Proteins Blueprint Program Output Results Directly linking the program and output from the same cell © 10X GENOMICS, INC. 2020. 32
Slide 33: Unlocking Rules of Epigenetic Programming
Unlocking Rules of Epigenetic Programming Epigenome RNA DNA Proteins Blueprint Program Output Results Directly linking the program and output from the same cell © 10X GENOMICS, INC. 2020. 33
Slide 34: High Concordance Between the Two Read-Outs
High Concordance Between the Two Read-Outs GEX ATAC 24,000 PBMCs © 10X GENOMICS, INC. 2020. 34
Slide 35: Dive Deep Where It Matters
Dive Deep Where It Matters Discover novel disease-specific open chromatin regions ATAC Monocytes 24kb Normal B cells Tumor B cells © 10X GENOMICS, INC. 2020. 35
Slide 36: Visium: Immunohistochemistry with Gene Expression
Visium: Immunohistochemistry with Gene Expression Immunohistochemistry (IHC) Visium Gene Expression IHC + Visium Gene Expression + = CD3 CD29 DAPI CD3 RNA Selected from a transcriptome Merged Note: Visium spatial gene expression with Immunofluorescence announced in June 2020. © 10X GENOMICS, INC. 20
Slide 37: Visium: Targeted Gene Expression
Visium: Targeted Gene Expression Whole Transcriptome, Standard Visium Reads per spot: 50,000 Pan-Cancer Panel Reads per spot: 10,000 Note: Targeted spatial gene expression expected launch date in Fall 2020. © 10X GENOMICS, INC. 2020. 37
Slide 38: Visium: FFPE on Spatial Gene Expression
Visium: FFPE on Spatial Gene Expression FFPE Recently fixed 7-year archival Standard tissue preservation Mouse brain Breast cancer Note: FFPE compatibility for Visium gene expression expected in 1H 2021. © 10X GENOMICS, INC. 2020. 38
Slide 39: Cell Ranger 4.0 Supports Our New Products
Cell Ranger 4.0 Supports Our New Products Getting to better results faster Targeted Gene Expression Cell Ranger Enhancements • 3’ and 5’ Gene Expression • Up to 4x faster runtime • Multi-sample aggregation • Dual-indexed read support • Support for custom panels © 10X GENOMICS, INC. 2020. 39
Slide 40: Towards a Comprehensive View of Biology
Towards a Comprehensive View of Biology Gene Expression Immunology DNA Epigenomics Proteins Chromium Single Cell Visium Spatial © 10X GENOMICS, INC. 2020. 40
Slide 41: © 10X GENOMICS, INC. 2020.
© 10X GENOMICS, INC. 2020. 41
10x Genomics — Morgan Stanley Virtual Healthcare Conference 2020 on 6ix